Blueprint Medicines Corp’s recent filing unveils that its Director Albers Jeffrey W. unloaded Company’s shares for reported $0.66 million on Mar 12 ’25. In the deal valued at $87.80 per share,7,500 shares were sold. As a result of this transaction, Albers Jeffrey W. now holds 152,396 shares worth roughly $13.65 million.
Then, Hewes L. Becker sold 5,232 shares, generating $458,804 in total proceeds. Upon selling the shares at $87.69, the CHIEF MEDICAL OFFICER now owns 30,419 shares.
Before that, Hewes L. Becker sold 4,863 shares. Blueprint Medicines Corp shares valued at $431,834 were divested by the CHIEF MEDICAL OFFICER at a price of $88.80 per share. As a result of the transaction, Hewes L. Becker now holds 35,651 shares, worth roughly $3.19 million.
Scotiabank initiated its Blueprint Medicines Corp [BPMC] rating to a Sector outperform in a research note published on March 07, 2025; the price target was $150. A number of analysts have revised their coverage, including JP Morgan’s analysts, who began to cover the stock in mid November with a ‘”an Overweight”‘ rating. UBS began covering BPMC with “Neutral” recommendation on October 24, 2024. Stephens started covering the stock on May 14, 2024. It rated BPMC as “an Overweight”.
Price Performance Review of BPMC
On Friday, Blueprint Medicines Corp [NASDAQ:BPMC] saw its stock fall -0.29% to $89.58. Over the last five days, the stock has gained 2.82%. Blueprint Medicines Corp shares have risen nearly 2.71% since the year began. Nevertheless, the stocks have fallen -0.13% over the past one year. While a 52-week high of $121.90 was reached on 01/27/25, a 52-week low of $80.68 was recorded on 03/10/25. SMA at 50 days reached $98.90, while 200 days put it at $97.46.
Levels Of Support And Resistance For BPMC Stock
The 24-hour chart illustrates a support level at 88.11, which if violated will result in even more drops to 86.63. On the upside, there is a resistance level at 90.95. A further resistance level may holdings at 92.31. The Relative Strength Index (RSI) on the 14-day chart is 41.29, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.06, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 58.86%. Stochastics %K at 44.38% indicates the stock is a holding.
How much short interest is there in Blueprint Medicines Corp?
A steep rise in short interest was recorded in Blueprint Medicines Corp stocks on 2025-02-28, growing by 0.5 million shares to a total of 4.71 million shares. Yahoo Finance data shows the prior-month short interest on 2025-01-31 was 4.21 million shares. There was a rise of 10.52%, which implies that there is a positive sentiment for the stock.
